Frederick, Maryland Jeffrey N. Hausfeld MD, MBA, Chairman and Chief Medical Officer, today announced that BioFactura will present at Biotech Showcase™ 2018, to be held January 8–10 during the most important week in healthcare at the Hilton San Francisco Union Square. Date: Wednesday, January 10, 2018 Time: 3:15 PM (PST) Room: Yosemite -B (Ballroom Level) Venue: … Continue reading
Annapolis, Maryland Today, Maryland Governor Larry Hogan signed into law a measure aimed at providing additional support to Maryland small biotechnology companies. Senate Bill 226 sponsored by Senator Roger Manno, and House Bill 373 sponsored by Delegate Darryl Barnes will support Maryland small and innovative biotech companies by amending the Biotechnology Investor Incentive Tax Credit … Continue reading
Frederick County’s commercial real estate industry was honored this evening at the inaugural Frederick Real Estate Dealmakers (FRED) Awards. Hosted by the Frederick County Office of Economic Development, the FRED Awards recognized the most successful commercial real estate transactions and projects of 2016 – and the people who made them happen. The impacts on Frederick County’s economy … Continue reading
BioFactura, Inc. was granted patent rights by China’s State Intellectual Property Office (SIPO) protecting the core technologies of its proprietary StableFastTM Biomanufacturing Platform. SIPO allowed 17 claims broadly covering composition of matter and methods. StableFastTM is BioFactura’s proprietary NS0-based system to rapidly generate stable cell lines that have the potential to lower cost, produce follow-on … Continue reading
Simran J. Kaur, Darryl Sampey, Lester W. Schultheis, Leonard P. Freedman and William E. Bentley. BioProcess International. October 2016. Biosimilars are biologically derived pharmaceuticals intended to have clinical similarity to a legally marketed innovator product when that product’s patent or market exclusivity has expired. By contrast with generic small-molecule drugs, clinical performance of a biologic … Continue reading
Biologic drugs offer highly effective medical treatments, but come with a hefty price tag. Creating biosimilar versions may change that… Continue reading
Getting biosimilars right at the manufacturing stage is vitally important, as there must be no clinically meaningful differences between the follow-on biologic and its reference product. Even small changes to cell lines can lead to major changes in how a biologic behaves, including its safety, efficacy and ability to trigger immune reactions. Creating an alliance with a biomanufacturing company… Continue reading
Momenta Pharmaceuticals has partnered on the development of an undisclosed biosimilar using BioFactura’s StableFast biomanufacturing platform… Continue reading
BioFactura, Inc., an emerging Maryland biopharmaceutical research and manufacturing company, announced today entry into a non-exclusive license agreement with Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, relating to one of the biosimilar product candidates that Momenta is developing. As part of this non-exclusive license agreement, … Continue reading
Megan M Illick, Luis M Branco, Joseph N Fair, Kerry A Illick, Alex Matschiner, Randal J Schoepp, Robert F Garry and Mary C Guttieri. Virology Journal 2008 … Continue reading